CRMP2 hyperphosphorylation is characteristic of Alzheimer's disease and not a feature common to other neurodegenerative diseases.
about
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's diseaseALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the diseaseControl of neuronal ion channel function by glycogen synthase kinase-3: new prospective for an old kinase.Interleukin-18 alters protein expressions of neurodegenerative diseases-linked proteins in human SH-SY5Y neuron-like cellsLate-onset Alzheimer's disease, heating up and foxed by several proteins: pathomolecular effects of the aging process.Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability?Soluble alpha-APP (sAPPalpha) regulates CDK5 expression and activity in neurons.CRMP4 and CRMP2 Interact to Coordinate Cytoskeleton Dynamics, Regulating Growth Cone Development and Axon ElongationOxidative stress-dependent phosphorylation activates ZNRF1 to induce neuronal/axonal degenerationLimiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation.Collapsin Response Mediator Protein-2 (CRMP2) is a Plausible Etiological Factor and Potential Therapeutic Target in Alzheimer's Disease: Comparison and Contrast with Microtubule-Associated Protein TauInteraction of aldehydes derived from lipid peroxidation and membrane proteinsIncreased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementiasLipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain.A novel mouse model for the identification of thioredoxin-1 protein interactions.GSK3 as a Sensor Determining Cell Fate in the Brain.The amyloid precursor protein intracellular domain-fe65 multiprotein complexes: a challenge to the amyloid hypothesis for Alzheimer's disease?Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.
P2860
Q22251067-CD9EA1CB-5CED-40D5-BE52-7C1147EB9755Q28392297-3EE826CA-786D-4846-9D7B-0A7E283BBB6FQ30465622-D7F91097-38AD-4AA4-8E8F-5EC6607CE5D9Q34014666-6185FD80-010D-4866-BB24-ADC549551A78Q34020079-6884ED7B-0BAB-4402-812D-B4CD2B70C506Q34570124-276AAFE1-6003-4E33-9C56-3451A54CFF83Q34776047-3591B84C-5CE7-453F-90DC-1247732908B9Q35639541-4BCA067B-1379-4D96-9CB8-72B7036155CFQ36310572-AB7AB9EB-727D-485E-88ED-A46C8062977FQ36661334-04A620AA-7AFD-4307-AD14-EB0587B8A819Q37089388-BC3B35ED-4B73-4F43-B812-ADF9E403D886Q37142547-F9361010-C665-4D29-BEA6-AFD8E3AC6045Q37243713-A00E91B3-DB3C-4F48-9837-321CA2A91F78Q38050263-EBF3780A-2FBD-4994-9FBB-4CFE9291C028Q39378624-3384696B-E07E-4CB6-9B31-063BC3A54E5CQ40963450-3B182953-1334-47D3-A78C-E7027F043E8DQ41899169-7801A9FA-B008-4D12-AA7B-EAE19FC8365FQ47113551-B1E76117-3B1B-4ED3-B22F-3A7886C77C58
P2860
CRMP2 hyperphosphorylation is characteristic of Alzheimer's disease and not a feature common to other neurodegenerative diseases.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
CRMP2 hyperphosphorylation is ...... er neurodegenerative diseases.
@en
CRMP2 hyperphosphorylation is ...... er neurodegenerative diseases.
@nl
type
label
CRMP2 hyperphosphorylation is ...... er neurodegenerative diseases.
@en
CRMP2 hyperphosphorylation is ...... er neurodegenerative diseases.
@nl
prefLabel
CRMP2 hyperphosphorylation is ...... er neurodegenerative diseases.
@en
CRMP2 hyperphosphorylation is ...... er neurodegenerative diseases.
@nl
P2093
P50
P356
P1476
CRMP2 hyperphosphorylation is ...... er neurodegenerative diseases.
@en
P2093
Adam R Cole
Alessia Usardi
Bettina Platt
David Howlett
David M A Mann
John Mayer
Lidy van Aalten
Lynn Bedford
P304
P356
10.3233/JAD-2011-110617
P577
2011-01-01T00:00:00Z